$38.0M
The financing round brings the total capital raised by the Paris based company to $100m.
A
Aqemia
Aqemia builds an artificial intelligence platform for drug discovery using atomic scale physics.
Paris, France—Founded 2024
$38.0MTotal raised
Aqemia develops an artificial intelligence platform for drug discovery that uses atomic scale physics rather than experimental training data. The Paris based company focuses on creating novel molecular structures for pharmaceutical applications.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Shareholders' funds
Members only
Current assets
Members only
Employees
Members only
Cash, assets and headcount from Aqemia's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
Maximilien Levesque
CEO and co-founder
Maximilien is the CEO and co-founder of Aqemia and serves on the board of France Biotech. He previously led a research group and taught machine learning, quantum mechanics, and theoretical chemistry at École normale supérieure.
LinkedIn